Avanos Medical (NYSE:AVNS – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.050-1.250 for the period, compared to the consensus earnings per share estimate of 1.670. The company issued revenue guidance of $665.0 million-$685.0 million, compared to the consensus revenue estimate of $713.1 million.
Avanos Medical Price Performance
NYSE:AVNS opened at $15.54 on Wednesday. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The business’s 50-day moving average price is $16.15 and its 200 day moving average price is $19.73. Avanos Medical has a 52-week low of $14.98 and a 52-week high of $25.36. The firm has a market cap of $714.36 million, a P/E ratio of 45.71 and a beta of 0.98.
Analyst Ratings Changes
Separately, StockNews.com lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 3rd.
About Avanos Medical
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Articles
- Five stocks we like better than Avanos Medical
- What is a buyback in stocks? A comprehensive guide for investors
- Tempus AI Is a Buy, If You Can Handle the Volatility
- Stock Market Sectors: What Are They and How Many Are There?
- Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders
- Airline Stocks – Top Airline Stocks to Buy Now
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.
